Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Brian Rini, MD, FASCO
Advertisement
Brian I. Rini, MD, FASCO, is the Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center and Ingram Professor of Medicine at Vanderbilt University in Nashville, Tennessee.
Articles by Brian Rini, MD, FASCO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Novel RIPTAC molecule shows promising activity in heavily pretreated mCRPC
2
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
3
LUGPA 2026: Midterms, AI, and ancillary services take center stage
4
CLARIFY trial reaches enrollment target for 64Cu-SAR-bisPSMA in prostate cancer
5